Chronic spontaneous urticaria
Drug research and approvals for chronic spontaneous urticaria: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 24 studies of chronic spontaneous urticaria are recruiting on ClinicalTrials.gov, Health Canada has authorized 28 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 24
- Trials authorized in Canada: 28
- FDA orphan approvals: 0
- EU medicines: 1
Recruiting Now
Newest start dates first, of 24 recruiting on ClinicalTrials.gov ↗- A Study of NN2802, an Anti-c-Kit Antibody, in Healthy Participants and in Adults With Chronic Spontaneous Urticaria…NCT07930572 · Phase 1 / Phase 2 · Novelty Nobility, Inc. · starts Oct 15, 2026
- Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous…NCT07816328 · Phase 3 · Novartis Pharmaceuticals · starts Sep 21, 2026
- A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)NCT07766499 · Phase 2 · Calixis Inc. · starts Sep 15, 2026
- Remibrutinib in Real-world Clinical Practice - a Germany Sub-study (REASSERT)NCT07642557 · Not reported · Novartis Pharmaceuticals · starts Aug 4, 2026
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity…NCT07717905 · Phase 1 / Phase 2 · Bambusa Therapeutics · starts Jun 29, 2026
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of…NCT07540910 · Phase 1 · Enanta Pharmaceuticals, Inc · starts Apr 1, 2026
- Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by…NCT07415551 · Phase 2 · Yuhan Corporation · starts Mar 26, 2026
- Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.NCT07402213 · Phase 3 · Jemincare · starts Mar 9, 2026
- Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous UrticariaNCT07378527 · Phase 2 / Phase 3 · Beijing InnoCare Pharma Tech Co., Ltd. · starts Feb 13, 2026
- Remibrutinib in Real-world Clinical Practice - a US Sub-studyNCT07358780 · Not reported · Novartis Pharmaceuticals · starts Feb 2, 2026
Trials Authorized in Canada
The 10 newest of 28; search them all in Canada trials| Feb 27, 2026 | A phase 3b long-term efficacy and safety extension study of barzolvolimab in participants with chronic spontaneous urticaria who have completed cdx0159-12 or…BARZOLVOLIMAB (CDX-0159) | CELLDEX THERAPEUTICS INC | Ongoing |
| Oct 10, 2024 | A phase 3 randomized, double-blind, placebo-controlled study to assess the efficacy and safety of barzolvolimab in patients with chronic spontaneous urticaria…BARZOLVOLIMAB (CDX-0159) | CELLDEX THERAPEUTICS INC | Ongoing |
| Oct 4, 2024 | A phase 3 randomized, double-blind, placebo-controlled study to assess the efficacy and safety of barzolvolimab in patients with chronic spontaneous urticaria…CDX-0159 | CELLDEX THERAPEUTICS INC | Ongoing |
| Aug 2, 2024 | An open-label extension study evaluating the safety, tolerability, pk, immunogenicity, and clinical response of multiple doses of iv ak006 in subjects with h1…AK006 | ALLAKOS INC. | Ongoing |
| Feb 8, 2024 | A phase 1, double-blind, randomized, placebo-controlled, sequential, singleand multiple- ascending dose study to evaluate the safety, tolerability, pk, and…AK006 | ALLAKOS INC. | Closed |
| Aug 18, 2023 | A global, multicenter, randomized, double-blind, double-dummy, parallel-group, phase 3b study to assess the efficacy, safety, and tolerability of remibrutinib…REMIBRUTINIB (LOU064) | Novartis Pharmaceuticals Corporation | Ongoing |
| Aug 15, 2023 | Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the effects of ep262 in subjects with chronic spontaneous urticariaEP262 | ESCIENT PHARMCEUTICALS INC | Closed |
| Mar 13, 2023 | A double-blind, randomized, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of remibrutinib (lou064) for 24 weeks in adolescents…REMIBRUTINIB (LOU064) | Novartis Pharmaceuticals Corporation | Ongoing |
| Dec 15, 2022 | A multicenter, open-label phase 3 study: ambulatory blood pressure monitoring in adult patients with chronic spontaneous urticaria inadequately controlled by…REMIBRUTINIB (LOU064) | Novartis Pharmaceuticals Corporation | Closed |
| Sep 26, 2022 | A multicenter, double-blind, placebo-controlled, randomized withdrawal and open-label extension study followed by long-term open-label treatment cycles to…REMIBRUTINIB (LOU064) | Novartis Pharmaceuticals Corporation | Ongoing |
Medicines Authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Apr 23, 2026 | Rhapsidoremibrutinib | Novartis Europharm Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA